Six Wellness Peptides Get Wider Prescription Access Under New HHS Policy. An Industry Player Praised is as a ‘Great Step.’

Six peptides marketed online for tissue repair, healthier skin and longevity will become more widely available through prescription compounding under a temporary federal policy, expanding access to substances whose advertised benefits remain scientifically unproven.

The Department of Health and Human Services announced Wednesday that compounding pharmacies could prepare BPC-157, TB-500, epitalon, MOTS-c, KPV and Semax for individual patients under specified conditions. The decision creates a prescription pathway intended to offer an alternative to unregulated sellers, but it does not grant Food and Drug Administration approval.

Dr. Bob Baravarian, a foot and ankle surgeon and owner of Alpha Bioscience Labs, which he describes as a U.S.-based peptide manufacturer, welcomed the announcement as an opportunity to improve accountability in the supply chain. He told IBT that it was "a great step in the right direction allowing compounding of certain peptides."

"By allowing compounding, we can now provide US manufactured peptides to patients and make sure there is certification, testing and purity tests to back up the peptides," he said. "This makes the need to buy gray market peptides unnecessary and adds safety for the end user."

HHS similarly framed its decision around patient choice and the risks associated with unregulated supplies. The policy requires patient-specific prescriptions, traceable ingredients, quality testing, and safety reporting.

Manufacturers supplying the bulk ingredients must meet applicable requirements, and certificates of analysis must document testing for identity, purity, potency, and contaminants. Those measures address sourcing and production. They do not establish that a peptide improves recovery, reverses aging, or delivers other benefits promoted online.

Peptides are molecules composed of amino acids, and the category includes established medicines as well as experimental substances. Insulin and GLP-1 medications demonstrate that peptide-based drugs can become approved treatments after clinical testing. Their success, however, does not establish the safety or effectiveness of unrelated compounds.

The six substances covered by the announcement have not established effectiveness through the evidence required for FDA approval. Their availability through a pharmacy should therefore not be interpreted as federal confirmation that they work for a particular condition.

The decision follows a July recommendation by an FDA advisory committee to add the six peptides to the 503A bulks list, which identifies substances eligible for use in certain compounded medications. FDA staff had recommended against inclusion, according to the HHS policy. The temporary approach allows conditional access while formal rulemaking continues.

Compounding involves combining or altering ingredients to prepare medication tailored to an individual patient. These products do not undergo the FDA's premarket review for safety, effectiveness, and quality.

Federal reviewers have raised concerns about peptide-related impurities, unwanted immune responses, and gaps in human safety information. Products obtained from unregulated sellers can also carry risks involving contamination or inaccurate dosing.